Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05876780 · ClinicalTrials.gov registry record · Phase 1
A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency)
A Phase 1 study of Limb Girdle Muscular Dystrophy, sponsored by Sarepta Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 2
- Study locations
NCT05876780 is a Phase 1 study of Limb Girdle Muscular Dystrophy that is active but no longer recruiting, run by Sarepta Therapeutics. The registered enrollment target is 6 participants, below the 239-participant average among 6 other Limb Girdle Muscular Dystrophy trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05876780, a Phase 1 study of Limb Girdle Muscular Dystrophy, is active but no longer recruiting, sponsored by Sarepta Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 2
- Study locations
Study Summary
The primary purpose of this study is to evaluate the safety of SRP-9003 and to quantify expression of β-SG in the skeletal muscle of participants with limb-girdle muscular dystrophy, type 2E/R4 (LGMD2E/R4). The study will include both ambulatory (Cohort 1) and non-ambulatory (Cohort 2) participants.
Conditions Studied
Interventions
- GENETIC SRP-9003
Study Locations (2)
Ohio
- Nationwide Children's Hospital - Columbus
Tennessee
- St. Jude Children's Research Hospital - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2022-12-19 |
| Est. Completion | 2028-08-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05876780
The ClinicalTrials.gov registry entry for NCT05876780 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 239-participant average among 6 other Limb Girdle Muscular Dystrophy trials with a reported enrollment target (97% lower). The listed sponsor is Sarepta Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Limb Girdle Muscular Dystrophy appearing as the primary indexed condition, and to 1 intervention - of which SRP-9003 is the first listed.
NCT05876780 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Ohio, Tennessee.
Frequently Asked Questions
What is clinical trial NCT05876780 about?
NCT05876780 is a clinical study titled "A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency)". The primary purpose of this study is to evaluate the safety of SRP-9003 and to quantify expression of β-SG in the skeletal muscle of participants with limb-girdle muscular dystrophy, type 2E/R4 (LGMD2E/R4). The study will include both ambulatory (Cohort 1) and non-ambulatory (Cohort 2) participants.
What is the current status of trial NCT05876780?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2022-12-19. Estimated completion is 2028-08-28.
What conditions does trial NCT05876780 study?
This clinical trial studies the following conditions: Limb Girdle Muscular Dystrophy.
What interventions are being tested in trial NCT05876780?
The interventions under investigation include: SRP-9003 (GENETIC).
Who is sponsoring clinical trial NCT05876780?
This trial is sponsored by Sarepta Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05876780 being conducted?
This trial has 2 study locations across Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Limb Girdle Muscular Dystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)
RECRUITING · Phase 1
-
LGMD R1 Natural History Study
RECRUITING
-
Molecular Analysis of Patients With Neuromuscular Disease
RECRUITING
-
A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4
ACTIVE NOT RECRUITING · Phase 3
-
A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice
ACTIVE NOT RECRUITING
-
Biomarker Development in LGMD2i
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.